Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 13, 2020- New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population- If successful, the REPAIR MR study has potential to expand MitraClip's current indication (patients at prohibitive risk for surgery) to also include patients at moderate risk- Jan 7, 2020- For people battling advanced heart failure, Abbott's HeartMate 3 heart pump can now be implanted through an incision in the chest wall versus open heart surgery- New, less invasive technique provides cardiac surgeons with the ability to choose the optimal surgical method for their patients
Nov 13, 2019- Mr. White will remain Executive Chairman of the Board- Mr. Ford has been elected to the Abbott Board- Nov 6, 2019- Discovery marks the first time a new subtype of HIV-1 has been identified since 2000- Abbott is making this new strain accessible to the research community to evaluate its impact to diagnostic testing, treatments and potential vaccines
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 21, 2019Abbott and the Australian Red Cross Blood Service extend 30-year partnership of providing safe, life-saving blood supply in Australia
- Oct 16, 2019- Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent- Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity- Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data
- Oct 15, 2019- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
-
Oct 15, 2019-- Oct. 17, 2019, marks the one-year anniversary of legalized recreational cannabis nationwide-- A year after legalization, 71% of Canadians are concerned about its impact on road safety-- Survey shows Canadians want more to be done to keep roads safe
Oct 14, 2019- Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care- As part of Omada's expanded Type 2 diabetes offering, FreeStyle Libre will be the exclusive CGM delivered directly to participants' doorsteps - expanding access to the technology for more people with diabetes-
Oct 7, 2019- Abbott volunteers work with teachers to empower students to take charge of their health, adopting healthy habits that last a lifetime- Initiative aims to inspire kids to take steps today to prevent chronic diseases tomorrow
- Sep 29, 2019- New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone- Data analyses presented at TCT demonstrated that over the lifetime of a typical COAPT patient, MitraClip showed improvements in both projected life expectancy and quality of life, and that those benefits are sustained through three years
- Sep 28, 2019- New data presented at TCT 2019 on Abbott's TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints- Abbott's TriClip tricuspid valve repair system design is based on the company's market-leading MitraClip™ technology
- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 17, 2019- World's smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects- Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart
- Sep 16, 2019- Abbott achieves top scores across all three key areas of economic, social and environmental performance, earns more than double the average score in Health Care Equipment & Supplies industry sector- Company's longstanding commitment to sustainability demonstrated by inclusion on DJSI for 15 consecutive years
- Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin- Two world leaders in diabetes work together to drive meaningful change in care
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Sep 9, 2019- New initiative will provide vital primary care services within a 30-minute walk of all Rwandans' homes- Health post workers will test and treat pregnant women for multiple infectious diseases that can have serious health consequences for both mothers and newborns if not diagnosed and treated early
Sep 6, 2019- Beckham will serve as spokesperson and creative director for Pedialyte- Pedialyte provides advanced rehydration, with an optimal balance of electrolytes and glucose- Sep 5, 2019- TRILUMINATE Pivotal trial is the world's first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation- There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid valves who are at high risk for surgery- Abbott's TriClip tricuspid valve repair system is built on the company's proven MitraClip technology
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 26, 2019- On Women's Equality Day, Abbott is publishing a blueprint for creating a high school STEM internship aimed at exposing young people, particularly girls, to STEM early and empowering other companies to download and use it- More than half of girls in a YouGov-Abbott survey say they aren't encouraged to study STEM, but 89% of girls who are urged to study STEM say they plan to pursue it in their educations
- Aug 14, 2019- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers- Collaboration is a major step in keeping roads safer as recreational marijuana legalization accelerates[1]
- Jul 17, 2019- Accelerated and sustainable growth driven by strong performance across portfolio- Raising full-year guidance for organic sales growth to 7 to 8 percent- Double-digit EPS growth exceeded expectations; raising full-year forecast- Long-term growth drivers - FreeStyle Libre, MitraClip and Alinity - achieving exceptional growth
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
- Jul 11, 2019- Alinity™ s System will screen the U.S. blood and plasma supply faster and more efficiently while maintaining highest levels of accuracy
- Jun 24, 2019- Real-world data from Advocate Health Care and Abbott shows prioritizing nutrition care for home health patients helped keep them out of the hospital- Improved health outcomes from nutrition intervention and educational support could help save millions of dollars in healthcare costs annually
-
Jun 18, 2019- Heart failure is a manageable condition, especially if it is detected early, but people are shying away from a conversation with their doctor because they are afraid of the diagnosis- Abbott, the global leader in heart failure treatment and technologies, is using this information to increase awareness and patient-physician dialogue as heart failure diagnoses are expected to rise 46% by 2030
- Jun 17, 2019- Program focused on helping people affected by conflict in Marawi City, Philippines- Chronic diseases are a critical but often overlooked problem in regions affected by disasters, conflict and other humanitarian challenges
- Jun 17, 2019- Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation- Assay is the first and only rapid point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes
- Jun 13, 2019- 45% of blood donations have historically come from people over 50 years old, but that number is declining1- As more millennials bring their passion to blood donation, they can fill the gap left by aging baby boomers- Abbott, the global leader in blood screening, is asking people of all generations to sign up to give blood and help save a life on World Blood Donor Day, June 14, and throughout the year
- Jun 8, 2019- Presented as a late-breaker at the American Diabetes Association (ADA) 79th Scientific Sessions, new real-world data demonstrate that monitoring glucose with FreeStyle Libre System has a positive impact among adults with Type 2 Diabetes who use multiple injections of insulin daily- Findings represent the first ever evaluation of real-world evidence specifically from the subset of people with Type 2 diabetes using Abbott's FreeStyle Libre system- Data underscore how actionable insights from the FreeStyle Libre system could help the more than 425 million people with diabetes1 globally make better decisions to improve diabetes management
- May 21, 2019- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR- Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation at 30 days- Study builds upon Abbott's success with its proven MitraClip™ clip-based technology in treating a similar disease on the left side of the heart
- May 16, 2019- Abbott's ZonePerfect Keto shakes and powders are formulated with a science-based macronutrient ("macros") ratio of 75% fat, 20% protein and 5% carbohydrates to support ketosis and burn body fat- ZonePerfect Keto helps fulfill a keto lifestyle on the go - offering the only true keto ready-to-drink option available nationwide at major retailers
- May 15, 2019- The YouGov-Abbott Student Loan Impact Survey shows 87% of those in college or graduating this year with student debt say finding a company with a student loan benefit is important to them- Additionally, over 6 in 10 working adults with student loans would consider switching to a company with a student loan employee benefit
- May 14, 2019- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies- The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
- May 6, 2019WORLD'S FIRST SMARTPHONE-COMPATIBLE IMPLANTABLE HEART MONITOR, ABBOTT'S CONFIRM Rx™ ICM OFFERS MORE ACCURATE DETECTION OF HEART RHYTHM DISORDERS
- May 2, 2019- WHO Prequalification approval allows Abbott to bring critical technology to more resource-limited settings- Confirms that the m-PIMA™ HIV-1/2 VL meets global standards of quality, safety and efficacy
- Apr 30, 2019-- Academic, military and healthcare leaders have come together to conduct a scientifically rigorous clinical trial of a blood test in development for the brain-- Research could lead to the first point-of-care blood test of its kind to help evaluate concussions within minutes
- Apr 29, 2019- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors- Abbott's core laboratory diagnostic test is the first troponin blood test with CE Mark that can more accurately predict risk of developing heart disease, when added to other heart disease risk assessments, than using other assessments alone